Welcome to our dedicated page for RADNOSTIX SEC filings (Ticker: INIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radnostix, Inc. filings document the public-company record of the radioisotope manufacturer formerly known as International Isotopes Inc. Recent 8-K and information-statement disclosures record the amendment to its Texas formation documents changing the corporate name, shareholder written-consent approval, and the continued OTCQB trading of its common stock under INIS.
Other filings and event reports cover executive-compensation arrangements, material agreements, shareholder voting matters, capital-structure disclosure, operating and financial results, and regulatory matters connected with radioisotope, theranostics, medical-device, calibration and reference products.
International Isotopes Inc. (INIS) reported an insider transaction on a Form 4. A reporting person who is both a Director and 10% Owner was granted a stock option to purchase 500,000 shares of common stock at an exercise price of $0.06 per share on 10/10/2025 (transaction code A).
The option becomes exercisable on 07/11/2026 and expires on 10/10/2035. Following the transaction, the insider beneficially owned 500,000 derivative securities, held directly.
International Isotopes Inc. (INIS) reported an insider equity award on Form 4. President & CEO and director Shahe Bagerdjian received 37,500,000 restricted stock units (RSUs) on October 9, 2025 under the company’s Amended and Restated 2015 Incentive Plan.
Each RSU represents a contingent right to receive one share of INIS common stock. The RSUs vest based on milestones tied to the company’s share price and available cash. Following the transaction, the filing shows 37,500,000 derivative securities beneficially owned, held directly, with a stated price of $0 for the RSUs.